♥ HF Guideline NavigatorESC 2026

9

9 Cardiovascular comorbidities

Pages 58–65 · open in PDF

Recommendations in this section

  • Class ILevel AOral anticoagulation is recommended in patients with clinical AF at elevated thromboembolic risk, as determined by CHA₂DS₂-VA score, to prevent ischaemic stroke and thromboembolism.
  • Class ILevel B1DOACs are recommended in preference to VKAs in patients with HF to prevent stroke and thromboembolism.
  • Class ILevel CBeta-blockers are recommended in stable patients with HFrEF and AF as first-line therapy for short- and long-term rate control.
  • Class IIaLevel CDigoxin should be considered in stable patients with HFrEF and AF when the ventricular rate remains high despite beta-blockers, or when beta-blockers are contraindicated/not tolerated, in order to obtain short- and long-term rate control.
  • Class IIaLevel B1Atrioventricular node ablation combined with CRT should be considered in patients with severely symptomatic permanent AF and poor rate control despite medical therapy and at least one HFH to reduce symptoms, physical limitations, recurrent HFH, and death.
  • Class IIbLevel CIntravenous amiodarone or digoxin may be considered in haemodynamically unstable patients with HFrEF and AF to stabilize the patient and achieve acute control of heart rate.
  • Class ILevel CUrgent cardioversion is recommended in the setting of DHF in patients presenting with rapid ventricular rates and haemodynamic instability to restore sinus rhythm.
  • Class IIaLevel CCatheter ablation for AF should be considered in selected patients with symptomatic AF and HFrEF to improve QoL and reduce the risk of HFH or death.
  • Class ILevel CCoronary revascularization is recommended in patients with HF, obstructive CAD, and persistent angina, despite FMT for HF and antianginal drugs, to relieve symptoms.
  • Class IIaLevel B1If revascularization is planned after assessment by a Heart Team, CABG should be considered as the preferred revascularization strategy, in patients with LVEF ≤ 35% and multivessel CAD suitable for surgery, to improve long-term survival.
  • Class ILevel B1Aortic valve intervention, SAVR or TAVI, is recommended in patients with severe aortic stenosis and HF to improve symptoms and reduce the risk of death.
  • Class ILevel B1Mitral transcatheter edge-to-edge repair is recommended in haemodynamically stable, symptomatic patients with HFrEF and persistent severe secondary mitral regurgitation despite optimized FMT and CRT if indicated, who fulfil specific clinical and echocardiographic criteria, in order to reduce the risk of HFH and improve
  • Class IIbLevel CMitral transcatheter edge-to-edge repair may be considered in selected symptomatic patients with HFrEF and persistent severe secondary mitral regurgitation despite optimized FMT and CRT if indicated (after excluding the option of LVAD or heart transplantation) who do not fulfil the specific clinical and echocardiographic criteria, in order to reduce the risk of HFH and improve QoL.

Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.

Page 58 · PDF

8.2.4. Symptom control and end-of-life care

Table 17 Indications and contraindications for heart transplantation

Advanced HF and no other therapeutic option (except for durable MCS as BTT) Absolute contraindications Inability to comply with the therapeutic regimen (e.g. dementia) Serious comorbidities with poor prognosis, not reversible with heart transplantation Other contraindications Active infectionb Severe peripheral arterial or cerebrovascular disease Elevated pulmonary vascular resistance (if pharmacologically irreversible)c Cancerd Irreversible liver dysfunction (cirrhosis) or irreversible kidney dysfunctione Systemic disease with multiorgan involvement BMI >35 kg/m2 or severe cachexia

Alcohol or substance abuse or active smoking within the past 6 months Psychological instability Insufficient social support to achieve compliant care in the outpatient setting

Eligibility for each option may change according to the specific conditions of each patient, which may also change over time. Some younger patients prefer to remain on LVAD for a prolonged period, rather than proceeding to transplantation immediately, to increase the potential number of life years gained. Other factors not related to the patient, such as average time on the heart transplantation waiting list, the centre’s surgical experience, and resources, can also influence decision-making.

Precipitating factors for AF – e.g. hyperthyroidism, toxic agents (e.g. including alcohol), valvular heart diseases, infection, diabetes, uncontrolled hypertension, obesity, sleep disorders, and volume overload – should be routinely identified and appropriately managed. Diuretic therapy is indicated to relieve congestion and may increase the chances of restoring sinus rhythm by reducing filling pressures and ventricular rate.

to FMT and GDIT, and without contraindications, to improve QoL and 622,626

FMT, foundational medical therapy; GDIT, guideline-directed interventional therapy; HF, heart failure; QoL, quality of life. a Class of recommendation. b Level of evidence. c Eligibility criteria are reported in Table 17.

Heart transplantation is recommended in selectedc patients with advanced HF refractory

9.1.1. Atrial fibrillation

9.1.1.1. Identification of triggers and risk factor management

Recommendation Table 14 — Recommendations for heart transplantation (see Evidence Tables 75 and 76) Classa

9.1. Arrhythmias and conduction disturbances Heart failure and AF frequently coexist, with AF occurring in more than half of patients with HF, and HF occurring in more than one-third of patients with AF. The prevalence of AF is slightly higher in patients with HFpEF compared with HFrEF.195,628–631 The two conditions are deeply interrelated with shared risk factors and pathophysiological mechanisms. The coexistence of HF and AF is associated with a high risk of death, HFH, and stroke regardless of LVEF.195,628–631 HF induced by AF appears to have a more favourable outcome than HF causing AF.13,632 The management of patients with HF and AF include identification of triggers, prevention of embolic events, management of HF, and rate or rhythm control of AF.

BMI, body mass index; BTT, bridge to transplantation; CPET, cardiopulmonary exercise testing; HF, heart failure; LVAD, left ventricular assist device; MCS, mechanical circulatory support; RHC, right heart catheterization. a Indication by heart transplantation centre includes assessment of HF severity by RHC and/or CPET. b Active infection is a relative contraindication to transplantation, but infected LVAD may be an indication. c LVAD as bridge to candidacy should be considered. d Highly selected cases may be eligible, to be discussed with an oncologist. e Combined heart–liver or heart–kidney transplantation may be considered.

9. Cardiovascular comorbidities

9.1.1.2. Prevention of embolic events Oral anticoagulation is recommended in patients with HF and AF to reduce the risk of thromboembolism, according to the CHA2DS2-VA score (Table 18).118,633–635 However, patients with HCM and CA are at higher risk of thromboembolism irrespective of CHA2DS2-VA score, and anticoagulation is recommended for all these patients with AF.636–642 In the absence of mechanical prosthetic heart valves and/or moderate

Advance care planning is recommended in parallel to advanced HF treatments to determine goals of care and improve QoL along the disease trajectory.627 For indications and the core components of end-of-life care, see Supplementary data online, Table S20. End-of-life care in advanced HF focuses on symptom management (including breathlessness, pain, and anxiety and depression), patient comfort, and maintaining QoL ensuring personalized, compassionate care. It involves clear communication, shared decisionmaking, and integrating palliative or hospice care to support both the patient and their family. For further details on symptom management, see Supplementary data online, Section S5.2.3. Patients on durable MCS may request withdrawal of lifesustaining treatments because these are no longer consistent with their goals of care, because of poor QoL or newly developed serious comorbidities such as cancer. The MCS may be deactivated after careful evaluation of the patient’s wish and by, or under the supervision of, a specialized team. This decision has to take national laws into account. For details regarding follow-up in patients with advanced HF see section 11.6.2 and Recommendation Table 26.

Page 59 · PDF

Updated definitions for the CHA2DS2-VA score Description

Stroke/transient ischaemic attack/arterial

Vascular disease (CAD and/or PAD)

CAD, coronary artery disease; CHA2DS2-VA, congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/transient ischaemic attack/arterial thromboembolism (2 points), vascular disease, age 65– 74 years; PAD, peripheral artery disease. A CHA2DS2-VA score of 2 or more is recommended as an indicator of elevated thromboembolic risk for decisions on initiating oral anticoagulation. A CHA2DS2-VA score of 1 should be considered an indicator of elevated thromboembolic risk for decisions on initiating oral anticoagulation.

or severe mitral stenosis, direct-acting oral anticoagulants are recommended as the anticoagulant of choice.643–646 Left atrial appendage closure can be an option for selected patients as described in the 2024 ESC Guidelines for the management of atrial fibrillation.118,647–651

9.1.1.3. Management of heart failure and atrial fibrillation All patients with coexisting HF and AF should be optimally treated with FMT, AMT, and GDIT regardless of AF (Section 6.2.4).435 In patients with AF and HFrEF, where there may be a high likelihood of LVEF recovery following rhythm control, evidence remains limited. However, given the well-established prognostic benefit of FMT on long-term prognosis in the general HFrEF population, initiation of FMT upfront seems reasonable. There is ongoing debate regarding the optimal management of AF in patients with HF. Currently, there is insufficient evidence to support a rhythm-control strategy over a rate-control strategy.337,652–658 Decisions with regard to choice of strategy must be made taking into account the cause–effect relationship between AF and HF, along with clinical presentation, symptom burden, stage of disease, comorbidities, and patient preference.

9.1.1.4. Rate control Data to support strict vs lenient rate control in patients with HF and AF are inconclusive. Analyses from a large observational registry showed a significant association between heart rate in AF and long-term death only in patients with HFrEF and heart rate >100 b.p.m.659,660 The RACE II trial demonstrated that lenient rate control (target heart rate <110 b.p.m.) was non-inferior to strict rate control (<80 b.p.m. at rest; <110 b.p.m. during exercise) in patients with permanent AF with a primary endpoint of death from CV causes, HFH, stroke, systemic embolism, bleeding, and life-threatening arrhythmic events.307 A post-hoc combined analysis from the AFFIRM and the RACE trials showed similar results.661 However, these trials were not focused on HF and only a minority of patients included had HF. A large observational study showed that a lenient rate-control strategy and poor rate control are associated with a higher risk

of death as compared with strict rate control in patients with AF and HF regardless of LVEF.662 Lenient rate control, with resting heart rate <110 b.p.m., should be considered as initial target in both patients with and without HF, with re-evaluation based on symptoms.118 Beta-blockers have proven safety and efficacy in patients with AF and HFrEF and are recommended as the first-line approach.663,664 If the ventricular rate control is suboptimal with beta-blockers, or if beta-blockers are not tolerated, digoxin or digitoxin should be considered.665–667 In patients with HFrEF who are haemodynamically unstable, i.v. amiodarone or digoxin may be used to achieve acute control of heart rate and improve haemodynamics, although acute electrical cardioversion to restore sinus rhythm should be first choice.668–671 There is no evidence on pharmacological strategies for rate control in patients with AF and HFpEF. Atrioventricular node ablation combined with CRT was found to be superior to pharmacological therapy in reducing death and HFH and improving QoL in patients with severely symptomatic permanent AF and HF, regardless of LVEF.672,673

9.1.1.5. Rhythm control The results of RCTs comparing catheter ablation vs pharmacological rhythm control in patients with HFrEF cannot be considered conclusive for hard outcomes on HFH and death, although catheter ablation has proven superior to antiarrhythmic treatment for AF recurrence.674–682 Data on the role of catheter ablation in HFpEF are limited.683,684 For a detailed description, see Supplementary data online, Section S6.1.1.674–681,683–686 Based on current evidence, catheter ablation should be considered only in carefully selected patients with HFrEF and symptomatic AF. This Task Force suggests that these criteria should be used to guide the selection of patients for catheter ablation: high burden AF,687 less than 1-year duration of continuous persistent AF, and a clear cause–effect relationship between AF and HF. In patients presenting with DHF, AF with rapid ventricular rates, and haemodynamic instability, urgent cardioversion is recommended. Pharmacological and electrical cardioversion seem to have similar outcomes, although specific studies in HF populations are lacking.688,689 Amiodarone is recommended in patients with HFrEF requiring pharmacological cardioversion. Other antiarrhythmic drugs, i.e. propafenone, flecainide, and dronedarone, are associated with poorer outcomes in HFrEF and should be avoided.690–694 There are no data on pharmacological cardioversion in HFpEF. Recommendation Table 15 — Recommendations for management of atrial fibrillation in patients with heart failure (see Evidence Tables 77–81) Recommendations

Recommendations for anticoagulation Oral anticoagulation is recommended in patients with clinical AF at elevated thromboembolic risk, as determined by CHA2DS2-VA scorec, to prevent ischaemic stroke and thromboembolism.635 Continued

Page 60 · PDF

VKAs in patients with HFd to prevent stroke and

thromboembolism. Rate control

Beta-blockers are recommended in stable patients with HFrEF and AF as first-line therapy for short- and long-term rate control.663,665 Digoxin should be considered in stable patients with HFrEF and AF when the ventricular rate remains high despite beta-blockers, or when beta-blockers are contraindicated/not

tolerated, in order to obtain short- and long-term rate control.665–667

Pacing indications in patients with HF do not differ from those without HF. However, long-term RV pacing can adversely impact LV function.706 In patients with HFrEF, where there is an expectation of high pacing requirements, i.e. complete heart block or AF with slow ventricular response, CRT implantation should be considered to improve outcomes (see Recommendation Table 7).409

Atrioventricular node ablation combined with CRT should be considered in patients with severely symptomatic permanent AF and poor rate control despite medical therapy and at least one HFH to reduce symptoms, physical

limitations, recurrent HFH, and death.672,673 Intravenous amiodarone or digoxin may be

9.2. Chronic coronary syndromes

considered in haemodynamically unstable patients with HFrEF and AF to stabilize the patient and achieve acute control of heart

Obstructive CAD is a frequent cause of HF.33 Coronary microvascular dysfunction affects up to 80% of patients with HFpEF and seems to be associated with poor prognosis.707–709 Diagnostic work-up of chronic coronary syndromes in patients with HF is described in Section 5. Treatment of chronic coronary syndrom in patients with established HF is described below.

rate.668–671 Cardioversion Urgent cardioversion is recommended in the setting of DHF in patients presenting with rapid ventricular rates and haemodynamic instability to restore sinus rhythm.669,671,692,695

Catheter ablation for AF should be considered in selectede patients with symptomatic AF and HFrEF to improve QoL and reduce the risk

of HFH or death.674–676,678,681,682,684,696 AF, atrial fibrillation; CHA2DS2-VA, congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/transient ischaemic attack/ arterial thromboembolism (2 points), vascular disease, age 65–74 years; CRT, cardiac resynchronization therapy; DHF, decompensated heart failure; DOAC, direct-acting oral anticoagulant; HF, heart failure; HFH, heart failure hospitalization; HFrEF, heart failure with reduced ejection fraction; QoL, quality of life; VKA, vitamin K antagonist. a Class of recommendation. b Level of evidence. c See Table 18. d Except for patients with moderate or severe mitral stenosis and in patents with mechanical prosthetic heart valves where VKAs are recommended. e All the following criteria are required: high burden AF, less than 1-year duration for continuous persistent AF, clear cause–effect relationship between AF and HF.

9.1.2. Ventricular arrhythmias Ventricular arrhythmias may cause HF or be a consequence thereof. In sustained ventricular tachycardia, initial management should include stabilization (electrical cardioversion), followed by identification and correction of precipitating factors, and optimization of FMT. Although amiodarone reduces ventricular arrhythmias, it does not reduce SCD or death.697 Patients with HF and resuscitated cardiac arrest or life-threatening ventricular arrhythmias have an indication for a secondary prevention ICD.119

Atrial fibrillation catheter ablation

Beta-blockers are recommended as first-line therapy in patients with HFrEF and CAD due to their prognostic effects, closely followed by other FMT drugs.288,290,291,710–712 Ivabradine should be considered in patients with HFrEF in sinus rhythm with heart rate >70 b.p.m. despite beta-blockers at the highest tolerated dose or if beta-blockers are contraindicated.294,713 Other medications such as amlodipine,714 felodipine,715 nicorandil,716 and ranolazine717 do not have effects on death but may improve symptoms. Trimetazidine may improve LV function and exercise capacity in patients with HFrEF and chronic coronary syndrome already on beta-blockers.718–720 Importantly, initiation and/or uptitration of antianginal therapy should not lead to reduction in FMT. Short-acting nitrates can cause hypotension and should be used with caution. Non-dihydropyridine calcium channel blockers (verapamil and diltiazem) are not recommended in patients with HFrEF due to their negative inotropic effects which may precipitate the risk of HF events.721 The use of beta-blockers or calcium channel blockers do not appear to be associated with worse outcomes in HFpEF.722,723 Treatment of patients with HFpEF should be similar to that of patients without HF (see the 2024 ESC Guidelines for the management of chronic coronary syndromes).10

9.2.2. Myocardial revascularization Data to support the prognostic benefit of myocardial revascularization in patients with stable obstructive CAD and HF are limited. Two RCTs compared revascularization vs medical therapy in patients with LVEF ≤35% and multivessel coronary disease.178–180 The STICH trial compared coronary artery bypass grafting (CABG) to medical therapy and showed survival benefit

Heart failure can occur because of frequent PVCs.698 A burden of PVCs of about 10% precipitates an increased risk of HF and the risk increases with higher burden.119,699–701 Thus, regular assessment of LVEF in this setting is indicated. Amiodarone may be considered to reduce recurrent arrhythmias and improve LV function,697 with regular follow-up to assess possible side effects. Catheter ablation of PVCs may improve LV function and, possibly, outcomes in patients with PVCs.702–705 For further details, please refer to the 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.119

DOACs are recommended in preference to

Page 61 · PDF

revascularization is planned, the multidisciplinary Heart Team should provide an individualized recommendation on the revascularization strategy—CABG or PCI—depending on patient characteristics. In case of persistent angina despite FMT for HF and antianginal drugs, revascularization is recommended regardless of LVEF. If the Heart Team agrees that revascularization is the best treatment option, in patients with HFrEF, LVEF ≤35% and multivessel disease, CABG should be the first choice (Figure 19). The Task Force recognizes an apparent discrepancy between the latter recommendation (class of recommendation IIa, level of evidence B1) and other recommendations in this context across other guidelines (e.g. 2024 ESC Guidelines for the management of chronic coronary syndromes, class of recommendation I, level

Figure 19 Management of coronary artery disease in patients with heart failure. BB, beta-blocker; CABG, coronary artery bypass grafting; CAD, coronary artery disease; FMT, foundational medical therapy; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention. Colours refer to class of recommendation. aExclusion of frailty, severe and multiple comorbidities and limited life expectancy making the risk of revascularization higher than the expected benefit. bPCI or continued medical therapy are alternative treatments if the patient is not eligible for CABG.

for CABG at long-term follow-up.179,180 The REVIVED-BCIS2 study compared percutaneous coronary intervention (PCI) and optimal medical therapy to optimal medical therapy alone and was neutral.178 The patient populations differed between the two trials and patients in REVIVED-BCIS2 were 10 years older, making comparison between them difficult. For details of these results and other studies, see Supplementary data online, Section S6.2.1.178,180,724–735 Patients with HF and chronic coronary syndrome due to obstructive CAD must receive FMT before revascularization. A multidisciplinary Heart Team discussion including an HF specialist is recommended to decide whether conservative treatment or an invasive treatment strategy should be adopted. If

Page 62 · PDF

control arm, mainly driven by WHF events.740 Therefore, treatment with a SGLT2-I is reasonable in these patients. Aortic valve intervention is recommended in all patients with HF and a life expectancy >1 year with high-gradient severe aortic stenosis, irrespective of LVEF, as well as in patients with severe low-flow low-gradient aortic stenosis and HFrEF. In patients with severe low-flow low-gradient aortic stenosis and HFpEF, aortic valve intervention should be considered. Details on diagnostic work-up, specific indications and the modality of intervention (TAVI vs surgery) are reported in the 2025 ESC/ EACTS Guidelines for the management of valvular heart disease.9

Recommendation Table 16 — Recommendations for revascularization in chronic coronary syndrome in patients with heart failure (see Evidence Table 82)

9.3.2. Aortic regurgitation

Severe aortic regurgitation can lead to LV dilatation and dysfunction which may progress to HF. Treatment with ACE-Is/ ARNIs/ARBs/MRAs while awaiting aortic valve intervention can be beneficial.741 Beta-blockers can prolong diastole and should be used only after careful consideration of risks and benefits. Specific recommendations for intervention are reported in the 2025 ESC/EACTS Guidelines for the management of valvular heart disease.9

Revascularization for symptom improvement (HFpEF and HFrEF) Coronary revascularization is recommended in patients with HF, obstructive CAD, and persistent angina, despite FMT for HF and

antianginal drugs, to relieve symptoms.734,735 Revascularization for outcome improvement (HFrEF)

9.3.3. Mitral regurgitation 9.3.3.1. Primary mitral regurgitation

If revascularization is planned after assessment

suitable for surgery, to improve long-term survival.180 CABG, coronary artery bypass grafting; CAD, coronary artery disease; FMT, foundational medical therapy; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction. a Class of recommendation. b Level of evidence.

9.3. Valvular heart disease 9.3.1. Aortic stenosis Aortic stenosis can contribute to or cause HF by increasing LV afterload.736 Prevalence of aortic stenosis ranges between 3% and 7% in patients with chronic HF and is higher in patients with HFpEF as compared with those with HFrEF.737 About 50% of patients with severe symptomatic aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) have HF.738 Once HF symptoms develop, prognosis is poor and timely valve intervention is mandatory. HF therapies may be used cautiously and should not delay valve intervention. After valve intervention, a clinical and echocardiographic reassessment is important to detect residual HF or risk of HF readmission. In this regard, further optimization of FMT as well as treatment of comorbidities and management of procedure-related factors is appropriate.739 In the recent open-label DapaTAVI trial, 1222 patients with history of HF and at least one risk factor (diabetes, CKD, LV dysfunction) were randomly assigned to receive either dapagliflozin or standard of care. At 1-year follow-up, the risk of the primary endpoint (death from any cause or WHF events) was reduced by 28% in the treatment arm as compared with the

by a Heart Team, CABG should be considered as the preferred revascularization strategy, in patients with LVEF ≤35% and multivessel CAD

Primary MR is caused by abnormalities of the valve apparatus and can lead to HF. In severe primary MR with HF symptoms, surgical repair is preferred over replacement whenever feasible.739,742,743 Mitral transcatheter edge-to-edge repair (TEER) should be considered in patients at high surgical risk.9,744,745

9.3.3.2. Secondary mitral regurgitation Secondary or functional MR is primarily a disease of the left cardiac chambers rather than the valvular apparatus. It is common in patients with HF, especially those with HFrEF in whom the disease has a prevalence of 25%.746,747 In order to adequately assess the severity of MR, the patient should be euvolaemic or as close to euvolaemia as possible. The underlying aetiology and severity of MR needs to be assessed by cardiologists specialized in echocardiography and structural heart diseases.748 A new classification, differentiating between atrial secondary MR and ventricular secondary MR has been recently proposed.9 Atrial secondary MR can be associated with HFpEF.749 Indications for mitral valve treatment in atrial secondary MR are reported in the 2025 ESC/EACTS Guidelines for the management of valvular heart disease.9 In patients with severe ventricular secondary MR and HFrEF, optimization of FMT and GDIT with CRT implantation (if indicated) is mandatory before considering any mitral valve intervention (Figure 20). In case of concomitant CAD requiring revascularization, specific recommendations on management are reported in the 2025 ESC/EACTS Guidelines for the management of valvular heart disease.9 In selected patients without need for coronary revascularization, TEER is recommended. Table 19 provides the clinical and echocardiographic criteria for patient selection, which are based on inclusion criteria from RCTs. For the results of these studies, see Supplementary data online, Section S6.3.1.750–754 If the criteria reported in Table 19 are not fulfilled, other options can be considered. Specifically, in

of evidence B). However, the patient populations that were considered are slightly different in the chronic coronary syndrome guidelines (often patients with chronic coronary syndrome presenting with reduced LVEF) as compared to these guidelines (often patients with HFrEF presenting with CAD). In addition, according to the most recent system for level of evidence grading, proposed by the ESC, the Task Force considered STICHES, with all its limitations (mean age 60 years, limited number of events at 10 years, limited use of modern FMT), as the only possible study available to support the recommendation.180

Page 63 · PDF

Figure 20 Management of secondary mitral regurgitation in patients with heart failure with reduced ejection fraction. CRT, cardiac resynchronization therapy; FMT, foundational medical therapy; HF, heart failure; LVAD, left ventricular assist device; MR, mitral regurgitation; TEER, transcatheter edge-to-edge repair. Colours refer to class of recommendation. aSee Table 19. bSee Figure 10.

Selection criteria for mitral transcatheter edge-to-edge repair in heart failure with reduced ejection fraction

Clinical and echocardiographic criteria Optimized FMT and other GDIT (i.e. CRT) if needed NYHA class ≥II At least one HFH within the last year OR Increased natriuretic peptide levels (BNP ≥300 pg/mL or NT-proBNP ≥1000 pg/mL) No stage D (advanced) HF No CAD requiring revascularization No hypertrophic, restrictive, or infiltrative cardiomyopathies LVEF 20%–50% LVESD ≤70 mm sPAP ≤70 mmHg No severe RV dysfunction No severe aortic and/or tricuspid valve disease BNP, B-type natriuretic peptide; CAD, coronary artery disease; CRT, cardiac resynchronization therapy; FMT, foundational medical therapy; GDIT, guideline-directed interventional therapy; HF, heart failure; HFH, heart failure hospitalization; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; TEER, transcatheter edge-to-edge repair; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; RV, right ventricular; sPAP, systolic pulmonary artery pressure.

Anatomy deemed suitable for mitral TEER

Page 64 · PDF

patients with advanced HF, LVAD or heart transplantation is recommended as first choice and TEER may be considered for symptom improvement in patients not suitable or waiting for these therapies (see Section 8) (Figure 20). Notably, patients with ventricular secondary MR experience a higher residual risk of death or HFH despite TEER.755,756 Thus, close follow-up in HF clinics is warranted.757 Recommendation Table 17 — Recommendations for valvular heart disease in patients with heart failure (see Evidence Tables 83 and 84) Recommendations

Aortic stenosis Aortic valve intervention, SAVR or TAVI, is recommended in patients with severe aortic stenosis and HFc to improve symptoms and reduce the risk of death.758–765

Secondary mitral regurgitation Mitral transcatheter edge-to-edge repair is recommended in haemodynamically stable, symptomatic patients with HFrEF and persistent severe secondary mitral regurgitation despite optimized FMT and CRT if indicated, who fulfil specific clinical and echocardiographic criteria,d in order to reduce the risk of HFH and improve QoL.750–753 Mitral transcatheter edge-to-edge repair may be considered in selected symptomatic patients with HFrEF and persistent severe secondary

the clinical and echocardiographic criteria for outcome improvement,d in order to improve symptoms.766–769 CRT, cardiac resynchronization therapy; FMT, foundational medical therapy; HF, heart failure; HFH, heart failure hospitalization; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction; QoL, quality of life; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation. a Class of recommendation. b Level of evidence. c This recommendation refers to patients with severe high gradient aortic stenosis regardless of LVEF and to patients with low-flow low-gradient aortic stenosis and HFrEF. For details regarding low-flow low-gradient aortic stenosis in HFpEF, we refer to the 2025 ESC/EACTS Guidelines for the management of valvular heart disease.9 d For clinical and echocardiographic criteria, see Table 19.

9.3.4. Tricuspid regurgitation Severe TR has a high prevalence (9%–20%) in both patients with HFpEF and HFrEF.747,770 Tricuspid regurgitation is currently classified as primary TR, CIED-related TR, and secondary TR. Secondary TR is most common.747,770 Medical therapy to target TR is limited.747,771 The development of transcatheter devices to treat TR provides an alternative to surgery in selected patients. Three RCTs are

mitral regurgitation despite optimized FMT and CRT if indicated (after excluding the option of LVAD or heart transplantation) who do not fulfil

Hypertension is common in patients with HF, especially those with HFpEF.454,777,778 In hypertensive heart disease, LV remodelling and LV hypertrophy lead to both diastolic and systolic impairment. Specific blood pressure targets for patients with hypertension and HF have not been evaluated in RCTs. In patients presenting with HF due to refractory hypertension, secondary causes [i.e. primary aldosteronism, renovascular hypertension, and obstructive sleep apnoea (OSA)] should be ruled out and treated.62 Indications for the treatment of hypertension in HF are reported in the 2024 ESC Guidelines for the management of elevated blood pressure and hypertension.62 Lifestyle interventions, such as increasing physical activity, optimizing weight, reducing salt and alcohol intake, and smoking cessation, are beneficial in all cases.62 The optimal treatment strategy for hypertension in patients with HFpEF is uncertain. FMT with effect on blood pressure (i.e. MRA) should be started, continued, or uptitrated. Loop diuretics reduce congestion and decrease blood pressure. In addition, ACE-Is, ARBs, and calcium channel blockers cause LV regression and therefore may be beneficial in both controlling blood pressure and improving HFpEF symptoms.62 Patients with HFpEF have limited preload reserve; therefore, normotension should be maintained and hypotension avoided. In patients with HFrEF, treatment strategies are similar to those for normotensive patients, as FMT also lowers blood pressure. Once FMT has been initiated and uptitrated, suboptimal blood pressure control is rare in HFrEF. If additional agents are required, amlodipine or felodipine may be considered provided the patient is euvolaemic.714,715 Alpha-blockers may be continued for the treatment of prostatic hyperplasia in the absence of hypotension but are not recommended for the treatment of hypertension in HFrEF. Non-dihydropyridine calcium channel blockers, e.g. verapamil and diltiazem, and central sympathetic agonists, e.g. moxonidine, are contraindicated due to poor outcomes in patients with HFrEF.779 In patients with HFrEF, asymptomatic hypotension should be accepted in order to maintain target doses of FMT.780

9.5. Stroke Heart failure and stroke share common risk factors. Approximately 10%–24% of patients with ischaemic stroke have concomitant HF either de novo or pre-existing.781–784 Conversely, patients with HF have an increased risk of stroke compared with those without.785 A history of stroke is reported

currently available that investigated the role of transcatheter treatments in patients with severe symptomatic TR. They showed a significant benefit in terms of QoL in patients receiving device therapy as compared with those treated conservatively, but without reduction of death or HFH at 1-year follow-up.772–774 Recently, a possible benefit in terms of HFH was reported in patients treated with tricuspid TEER, but with a high rate of crossover after 1-year follow-up.775,776 It should be noted that all these studies were unblinded and did not focus on HFpEF or HFrEF populations. Indications for TR treatment are reported in the 2025 ESC/ EACTS Guidelines for the management of valvular heart disease.9

Page 65 · PDF

demonstrated favourable effects of the GLP-1 RA semaglutide and the dual GIP/GLP-1 RA tirzepatide in patients with HFpEF and obesity regardless of diabetes status, namely reduction of body weight, improvement of QoL, symptoms, and functional capacity (see Supplementary data online, Section S7.1).315–317 Pooled and secondary analyses of RCTs, and the recent SUMMIT trial, have also suggested a potential benefit of these drugs on HF events.317,819,820 Dedicated RCTs are needed to evaluate safety and efficacy of these drugs in patients with HFrEF and to assess long-term follow-up.821,822 In propensity score-matched cohort studies, bariatric surgery was associated with weight loss and a lower risk of all-cause and CV death, HFH, and AF as compared to medical therapy in patients with HF and a BMI ≥35 kg/m2, with consistent benefits observed among patients with HFrEF and HFpEF.823,824 Studies comparing bariatric surgery vs new anti-obesity medications are lacking, and the indications for bariatric surgery may change in the future. Recommendation Table 18 — Recommendations for obesity in patients with heart failure (see Evidence Tables 85 and 86) Recommendations

10. Non-cardiovascular comorbidities

Semaglutide or tirzepatide should be considered

and BMI ≥30 kg/m2, regardless of diabetes status, to reduce body weight, and improve

for patients with symptomatic HF, LVEF ≥45%,

exercise capacity and QoL.315–317,819,820,825 Bariatric surgery may be considered in obese patients with HF and a BMI ≥35 kg/m2 to reduce body weight when repetitive and structured lifestyle changes combined with weight-reducing medications do not result in maintained weight loss.823,824 BMI, body mass index; HF, heart failure; LVEF, left ventricular ejection fraction; QoL, quality of life. a Class of recommendation. b Level of evidence.

10.2. Diabetes Patients with HF who have T2DM have a poorer prognosis than patients who do not have T2DM.826–828 The diagnostic process and therapeutic approach to HF in patients with T2DM is the same as the population without T2DM. There is no evidence that the efficacy of FMT is altered by the presence of T2DM.241,829–833 60 The 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes dedicated a specific section to the treatment of diabetes in patients with HF.60 Sodium–glucose co-transporter 2 inhibitors have been investigated in different populations with diabetes, ranging from patients with ASCVD or multiple ASCVD risk factors to patients with established HF across the entire range of LVEF or recently hospitalized for WHF, with greater absolute risk reduction of clinical events in patients at higher risk.834 Thus, the use of

Obesity contributes to the development of well-known CV and HF risk factors like hypertension, diabetes, and dyslipidaemia. Obesity has direct adverse effects on cardiac structure and function, and is associated with the development of CVD, including HF.808 Patients with HF and obesity may have lower natriuretic peptide concentrations due to increased expression of clearance receptors, augmented peptide degradation by the adipose tissue,155 and underestimation of circulatory congestion.809 Peak oxygen consumption adjusted for body weight underestimates exercise capacity in obese patients, and an adjustment for lean body mass should be used for risk stratification pro-inflammatory.810 A stronger association between obesity and HFpEF rather than HFrEF has been described.778,811 Among patients with HFpEF, the obesity-related phenotype has a high prevalence (30%–40% in Europe and 60%–70% in North America).314,812 These patients display several pathophysiological mechanisms that differ from non-obese patients with HFpEF.813 An increase in adipocyte mass induces a state of systemic inflammation and a proinflammatory transformation of epicardial adipose tissue that may lead to fibrosis. The capacity of the left ventricle to dilate in response to an increase in blood volume is impaired, and thus, even modest degrees of volume overload may lead to cardiac overfilling and disproportionate increase in cardiac filling pressures.814 On average, patients with HFpEF and obesity are younger, experience worse HF signs and symptoms, poorer QoL, and worse functional capacity, than those without obesity.815,816 Weight-loss interventions in patients with HFpEF and obesity alleviate symptoms and may improve outcomes. Lifestyle interventions, such as caloric restriction, exercise, and patient education, have a significant impact on body weight and are recommended in all patients with HF.817,818 Recent RCTs

in 8%–11% patients with HF785–789 with similar790–794 or increased795,796 prevalence in patients with HFpEF compared with HFrEF. Poorer outcomes after stroke are observed in patients with HF with a 2.2–4.5 times higher rate of death compared with people without HF,782,783,797 as well as an increased rate of recurrent stroke.798 The risk of stroke in patients with HF seems independent of rhythm, with an annualized stroke risk of 2.0 per 100 patientyears in patients in sinus rhythm and 2.87 per 100 patient-years in patients with AF.799–802 However, RCTs failed to demonstrate a possible benefit of oral anticoagulation in patients with HFrEF in sinus rhythm.803–806 Thus, in the absence of AF, there is no evidence to recommend routine anticoagulation for stroke prevention in patients with HFrEF. Optimization of blood pressure, heart rate, and cardiac output immediately after a stroke is key to reducing the risk of DHF and improving outcomes. In patients already established on FMT, treatment with FMT should be maintained if possible and attention should be paid to dose modification in order to avoid both hypo- and hypertension as well as rebound tachycardia in patients in whom beta-blockers have been withdrawn.807 Following the acute phase, treatment of HF in patients with stroke does not differ from treatment in patients without stroke.